Additional file 1 of Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Pattni, Karan; Hungerford, Daniel; Adams, Sarah; Buchan, Iain; Cheyne, Christopher P.; García-Fiñana, Marta; Hall, Ian; Hughes, David M.; Overton, Christopher E.; Zhang, Xingna; Sharkey, Kieran J.

doi:10.6084/m9.figshare.19388922.v1

12879_2022_7239_MOESM1_ESM.pdf (5.55 MB)

Additional file 1 of Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

journal contribution

posted on 2022-03-21, 04:10 authored by Karan Pattni, Daniel Hungerford, Sarah Adams, Iain Buchan, Christopher P. Cheyne, Marta García-Fiñana, Ian Hall, David M. Hughes, Christopher E. Overton, Xingna Zhang, Kieran J. Sharkey

Additional file 1. Population demographics, MCMC output (parameter estimates, trace plots and posterior distributions) for all models and log likelihood profile for infectiveness.

Funding

Engineering and Physical Sciences Research Council National Institute for Health Research (GB) National Institute for Health Research

History

Usage metrics

Keywords

SARS-CoV-2 COVID-19 Vaccine SIR Modelling Infectious disease Effectiveness

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Funding

Engineering and Physical Sciences Research Council National Institute for Health Research (GB) National Institute for Health Research

History

Usage metrics

Categories

Keywords

Licence

Exports